You have accessJournal of UrologyRenal Transplantation & Vascular Surgery I (MP37)1 Sep 2021MP37-04 PREOPERATIVE REBOUND OF ANTI-ABO BLOOD TYPE ANTIBODY IS A RISK FACTOR OF ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT RECIPIENTS EVEN IN RITUXIMAB ERA Ryohei Yamamoto, Mitsuru Saito, Ryuichiro Sagehashi, Takuro Saito, Soki Kashima, Atsushi Koizumi, Taketoshi Nara, Kazuyuki Numakura, Shintaro Narita, Shintaro Narita, Shigeru Satoh, and Tomonori Habuchi Ryohei YamamotoRyohei Yamamoto More articles by this author , Mitsuru SaitoMitsuru Saito More articles by this author , Ryuichiro SagehashiRyuichiro Sagehashi More articles by this author , Takuro SaitoTakuro Saito More articles by this author , Soki KashimaSoki Kashima More articles by this author , Atsushi KoizumiAtsushi Koizumi More articles by this author , Taketoshi NaraTaketoshi Nara More articles by this author , Kazuyuki NumakuraKazuyuki Numakura More articles by this author , Shintaro NaritaShintaro Narita More articles by this author , Shintaro NaritaShintaro Narita More articles by this author , Shigeru SatohShigeru Satoh More articles by this author , and Tomonori HabuchiTomonori Habuchi More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002046.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Because ABO blood-type incompatible kidney transplantation (ABOI-KT) has a potential of acute antibody-mediated rejection (ABMR), desensitization therapies including antibody removal and administration of rituximab are mandatory. Rituximab, anti-CD20 antibody, can deplete B lymphocyte, this reportedly makes easy to regulate the antibody production and “rebound phenomenon” after antibody removal. Even in rituximab era, we sometimes encounter the cases presenting rebound of anti-ABO blood-type antibody in ABOI-KT, however, the clinical significance has not been clarified yet. METHODS: From November 2005 to May 2019, 70 patients received ABOI-KT in Akita University Hospital and were enrolled in this study. All patients were administered rituximab with 200 mg/body once at 3 weeks before transplantation. The other immunosuppressive agents such as mycophenolate mofetil with 1500 mg/day (from 3 weeks before KT), tacrolimus (from 1 week before KT; target trough level is 8-10 ng/mL) and methylprednisolone with 80 mg/day (from 1 week before KT) were also administered. To decrease the antibody titer, several sessions of antibody removal were performed (our target titer is 1:32 or lower). The rebound of antibody in this study was defined as that the baseline titer was ≥1:32 and if the titer returned to the level prior to antibody removal. We investigated the risk factors of antibody rebound and its relationship with ABMR within 1 month after KT. RESULTS: The mean age of patients at KT was 54±10 years old. Baseline titer was as follows; ≤1:64 was 47 patients (67%), 1:128 was 10 (14%), 1:256 was 8 (11%), 1:512 was 4 (6%), and ≥1:1048 was 1 (2%). The cases presenting rebound was 20 (29%, the rebound group). Ten cases (14%) developed ABMR within 1 month after KT. In multivariate analysis, baseline titer ≥1:128 was one of the independent risk factors for antibody rebound (p=0.001). There was no relationship between the antibody titer at baseline, antibody titer immediately before transplant and ABMR. However, the incidence of ABMR was significantly higher in the rebound group than in the non-rebound cases (p=0.004). In multivariate analysis, “rebound” was one of the independent risk factors for ABMR (p=0.003). CONCLUSIONS: The preoperative rebound in ABOI-KT was a risk factor of ABMR. In the kidney transplant recipients presenting rebound preoperatively, we have to monitor them carefully after ABOI-KT even in rituximab era. Source of Funding: none © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e646-e646 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ryohei Yamamoto More articles by this author Mitsuru Saito More articles by this author Ryuichiro Sagehashi More articles by this author Takuro Saito More articles by this author Soki Kashima More articles by this author Atsushi Koizumi More articles by this author Taketoshi Nara More articles by this author Kazuyuki Numakura More articles by this author Shintaro Narita More articles by this author Shintaro Narita More articles by this author Shigeru Satoh More articles by this author Tomonori Habuchi More articles by this author Expand All Advertisement Loading ...